AOD-9604
Targeted Lipolysis Without IGF-1 Stimulation
AOD-9604 — Modified GH Fragment (hGH 176-191)
Last reviewed: April 2026
What is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. Unlike full-length hGH, AOD-9604 retains the lipolytic (fat-burning) activity of the parent molecule without stimulating IGF-1 production or promoting cell proliferation. It received FDA GRAS designation in 2014 and has completed Phase II and Phase III clinical trials for obesity.
Molecular Composition
AOD-9604 consists of 16 amino acids corresponding to the C-terminal fragment of hGH (positions 176–191), with a disulfide bridge between Cys182 and Cys189. This fragment contains the region responsible for hGH's lipolytic activity while lacking the N-terminal domain required for IGF-1 stimulation and cell proliferation.
How Does It Work?
AOD-9604 reduces body fat by activating beta3-adrenergic receptors in adipose tissue to stimulate lipolysis, without the growth-promoting effects of full-length hGH.
AOD-9604 activates beta3-adrenergic receptors in adipose tissue, stimulating cAMP-mediated lipolysis and increasing fatty acid oxidation. Simultaneously, it suppresses acetyl-CoA carboxylase activity, reducing de novo lipogenesis and triglyceride synthesis. Unlike full-length hGH, it does not activate the JAK2/STAT5 pathway responsible for IGF-1 production.
AOD-9604 is a fragment of human growth hormone engineered to retain only the fat-burning properties of hGH while eliminating the growth-promoting and blood-sugar-disrupting effects. It received FDA GRAS status in 2014 and completed Phase III clinical trials for obesity.
AOD-9604 activates fat cells' beta3-adrenergic receptors, triggering lipolysis (fat breakdown) and blocking lipogenesis (new fat creation). It does this without raising IGF-1 or insulin, which distinguishes it from full-length growth hormone.
Most fat-loss peptides work indirectly through appetite suppression or growth hormone release. AOD-9604 acts directly on fat cells, making it a mechanistically distinct tool for metabolic research. Its FDA GRAS status and Phase III safety data give it one of the strongest regulatory profiles of any research peptide.
AOD-9604 is a GH-derived fat metabolism peptide with FDA GRAS status and Phase III clinical trial data. Its targeted lipolytic mechanism and clean safety profile make it a valuable tool for metabolic research.
Key Research Pathways
Beta3-Adrenergic Receptor Activation
Activates beta3-adrenergic receptors in adipose tissue, stimulating cAMP-mediated lipolysis and increasing fatty acid oxidation independent of IGF-1 signaling.
Lipogenesis Inhibition
Suppresses acetyl-CoA carboxylase activity, reducing de novo lipogenesis and triglyceride synthesis in adipocytes.
GH Receptor Partial Agonism
Binds GH receptor with lower affinity than full-length hGH, activating metabolic pathways without triggering the full mitogenic or diabetogenic effects of hGH.
Key Findings from the Literature
- FDA GRAS (Generally Recognized as Safe) designation granted in 2014
- Phase IIb trials showed statistically significant reductions in body weight vs placebo
- No adverse effects on blood glucose, insulin sensitivity, or IGF-1 levels in clinical trials
- Stimulates lipolysis and inhibits lipogenesis through beta3-adrenergic receptor activation
- Completed Phase III clinical trials for obesity treatment
Evidence by Claimed Outcome
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Pharmacokinetics
AOD-9604 — absorption, distribution, metabolism, and excretion data
| Parameter | Value | Source |
|---|---|---|
| Half-Life (t½) | ~30 minutes (SC) Short half-life; SC preferred for lipolytic effects | Clinical Trial Data |
| Time to Peak (Tmax) | ~15–30 minutes (SC) After subcutaneous injection | Clinical Trial Data |
| Bioavailability (F) | SC: estimated 70–80%; Oral: very low Oral bioavailability is minimal | Clinical Trial Data |
| Onset of Action | 30–60 minutes Lipolytic effects begin within 30–60 min of SC injection | — |
| Duration of Action | 2–4 hours per dose Multiple daily doses used in protocols | — |
C-terminal fragment of human growth hormone (hGH176-191). Retains lipolytic activity of hGH without the anabolic or diabetogenic effects. Phase 2 clinical trials for obesity completed.
References:
• Heffernan M et al. J Endocrinol 2001
• Ng FM et al. J Mol Endocrinol 1990
Important Research Context
AOD-9604
Metabolic Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
Technical Specifications
| Peptide Class | GH fragment (hGH 176-191) |
| Molecular Weight | 1,817.1 Da |
| Regulatory Status | FDA GRAS designation (2014); Phase III completed |
| Available Sizes | 2mg, 5mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Known Interactions
6 documented interactions for AOD-9604
Both affect fat metabolism. AOD-9604 via lipolysis; semaglutide via appetite suppression and metabolic effects. Theoretical additive effect — monitor for excessive fat loss.
Both affect fat metabolism. Monitor for excessive fat loss when combining.
AOD-9604 targets fat metabolism; BPC-157 targets tissue repair. No known interaction.
AOD-9604 targets fat metabolism; IGF-1 LR3 targets muscle growth. No known negative interaction.
Interaction data is based on published research, known pharmacological mechanisms, and clinical practitioner experience. Evidence tiers: Clinical = human data; Emerging = preclinical/case reports; Theoretical = mechanism-based inference. Always consult a qualified healthcare provider before combining compounds.
Source AOD-9604 at Purgo Labs
≥99% purity · Third-party COA · Use code HEALTH for 15% off
Other Compounds in This Guide
Related Research Guides
Get the AOD-9604 Protocol Guide
Dosing protocols, cycle timing, stacking strategies, and sourcing checklist — delivered free to your inbox.
Ready to Source AOD-9604?
Purgo Labs offers AOD-9604 with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase AOD-9604 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.